Fig. 5.
Expression of Lck in EBV-transformed B cells. (A) Immunoblot analysis using an anti-Lck MoAb of lysates from EBV-transformed lymphoblastoid B-cell lines, or Daudi, Raji, and RPMI-1788 B-cell lines. A lysate from normal T cells is included as a positive control, as well as a lysate from normal peripheral blood B cells as a negative control (PB). (B) Immunoblot analysis using an anti-Lck MoAb of lysates from either freshly isolated peripheral B cells from healthy controls (PB1, PB2) or EBV-transformed lymphoblastoid B-cell lines from the same controls (B-EBV1, B-EBV2). A lysate from normal T cells is included as a positive control.

Expression of Lck in EBV-transformed B cells. (A) Immunoblot analysis using an anti-Lck MoAb of lysates from EBV-transformed lymphoblastoid B-cell lines, or Daudi, Raji, and RPMI-1788 B-cell lines. A lysate from normal T cells is included as a positive control, as well as a lysate from normal peripheral blood B cells as a negative control (PB). (B) Immunoblot analysis using an anti-Lck MoAb of lysates from either freshly isolated peripheral B cells from healthy controls (PB1, PB2) or EBV-transformed lymphoblastoid B-cell lines from the same controls (B-EBV1, B-EBV2). A lysate from normal T cells is included as a positive control.

Close Modal

or Create an Account

Close Modal
Close Modal